Literature DB >> 30148072

CRISPR-based genetic interaction maps inform therapeutic strategies in cancer.

Poornima Ramkumar1, Martin Kampmann1,2.   

Abstract

Entities:  

Year:  2018        PMID： 30148072      PMCID： PMC6107073          DOI： 10.21037/tcr.2018.01.02

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  24 in total

Review 1.  Imatinib mesylate--a new oral targeted therapy.

Authors:  David G Savage; Karen H Antman
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

Review 2.  Multi-target therapeutics: when the whole is greater than the sum of the parts.

Authors:  Grant R Zimmermann; Joseph Lehár; Curtis T Keith
Journal:  Drug Discov Today       Date:  2006-11-28       Impact factor: 7.851

3.  Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.

Authors:  Karina A Kruth; Mimi Fang; Dawne N Shelton; Ossama Abu-Halawa; Ryan Mahling; Hongxing Yang; Jonathan S Weissman; Mignon L Loh; Markus Müschen; Sarah K Tasian; Michael C Bassik; Martin Kampmann; Miles A Pufall
Journal:  Blood       Date:  2017-04-19       Impact factor: 22.113

4.  Genetic interaction mapping in mammalian cells using CRISPR interference.

Authors:  Dan Du; Assen Roguev; David E Gordon; Meng Chen; Si-Han Chen; Michael Shales; John Paul Shen; Trey Ideker; Prashant Mali; Lei S Qi; Nevan J Krogan
Journal:  Nat Methods       Date:  2017-05-08       Impact factor: 28.547

Review 5.  CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine.

Authors:  Martin Kampmann
Journal:  ACS Chem Biol       Date:  2017-10-24       Impact factor: 5.100

6.  Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras.

Authors:  Tim Wang; Haiyan Yu; Nicholas W Hughes; Bingxu Liu; Arek Kendirli; Klara Klein; Walter W Chen; Eric S Lander; David M Sabatini
Journal:  Cell       Date:  2017-02-02       Impact factor: 41.582

7.  Quantitative genetic-interaction mapping in mammalian cells.

Authors:  Assen Roguev; Dale Talbot; Gian Luca Negri; Michael Shales; Gerard Cagney; Sourav Bandyopadhyay; Barbara Panning; Nevan J Krogan
Journal:  Nat Methods       Date:  2013-02-13       Impact factor: 28.547

8.  A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility.

Authors:  Michael C Bassik; Martin Kampmann; Robert Jan Lebbink; Shuyi Wang; Marco Y Hein; Ina Poser; Jimena Weibezahn; Max A Horlbeck; Siyuan Chen; Matthias Mann; Anthony A Hyman; Emily M Leproust; Michael T McManus; Jonathan S Weissman
Journal:  Cell       Date:  2013-02-08       Impact factor: 41.582

9.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

10.  Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions.

Authors:  John Paul Shen; Dongxin Zhao; Roman Sasik; Jens Luebeck; Amanda Birmingham; Ana Bojorquez-Gomez; Katherine Licon; Kristin Klepper; Daniel Pekin; Alex N Beckett; Kyle Salinas Sanchez; Alex Thomas; Chih-Chung Kuo; Dan Du; Assen Roguev; Nathan E Lewis; Aaron N Chang; Jason F Kreisberg; Nevan Krogan; Lei Qi; Trey Ideker; Prashant Mali
Journal:  Nat Methods       Date:  2017-03-20       Impact factor: 28.547
View more
  2 in total

Review 1.  CRISPR in cancer biology and therapy.

Authors:  Alyna Katti; Bianca J Diaz; Christina M Caragine; Neville E Sanjana; Lukas E Dow
Journal:  Nat Rev Cancer       Date:  2022-02-22       Impact factor: 60.716

Review 2.  Applications of CRISPR-Cas Technologies to Proteomics.

Authors:  Georgii Dolgalev; Ekaterina Poverennaya
Journal:  Genes (Basel)       Date:  2021-11-12       Impact factor: 4.096
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.